1-deoxynojirimycin has been researched along with glycogen in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| De Wit, LE; Hülsmann, WC; Schoonderwoerd, K; Stam, H | 1 |
| Bollen, M; Stalmans, W | 1 |
| Reuser, AJ; van Dongen, JM; Wisselaar, HA | 1 |
| Reuser, AJ; Wisselaar, HA | 1 |
| Ermert, P; Garman, EF; Johnson, LN; Mitchell, EP; Oikonomakos, NG; Vasella, AT; Withers, SG | 1 |
| Depre, C; Hue, L | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Higashioka, M; Kariya, T; Minatoguchi, S; Takatsu, H; Takemura, G; Uno, Y; Yoshikuni, Y | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Kariya, T; Kawasaki, M; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y | 1 |
| Andersson, U; Butters, TD; Dwek, RA; Platt, FM | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Higashioka, M; Kumada, H; Kuwano, K; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N | 1 |
| Arai, M; Fujiwara, H; Fujiwara, T; Hashimoto, K; Hashimoto, Y; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N; Wu, DJ | 1 |
| Arai, M; Chen, XH; Fujiwara, H; Fujiwara, T; Hashimoto, K; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N | 1 |
| Andersson, U; Butters, TD; Dwek, RA; Platt, FM; Reinkensmeier, G | 1 |
| Feng, J; Flanagan, JJ; Frascella, M; Guillen, D; Khanna, R; Lockhart, DJ; Lun, Y; Pellegrino, LJ; Soska, R; Valenzano, KJ | 1 |
| Brignol, N; Dhulipala, R; Do, HV; Feng, J; Frascella, M; Garcia, A; Khanna, R; Lockhart, DJ; Lun, Y; Pellegrino, LJ; Powe, AC; Soska, R; Toth, MJ; Valenzano, KJ; Wustman, BA; Xu, S | 1 |
| Do, HV; Feng, J; Frascella, M; Garcia, A; Gotschall, R; Khanna, R; Lun, Y; Martina, JA; Nair, A; Ponery, AS; Puertollano, R; Raben, N; Ralston, E; Schilling, A; Soska, R; Tuske, S; Valenzano, KJ; Valle, MCD; Xu, S | 1 |
| Blair, HA | 1 |
2 review(s) available for 1-deoxynojirimycin and glycogen
| Article | Year |
|---|---|
An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Animals; Blood Glucose; Carbohydrate Sequence; Contraindications; Diabetes Mellitus; Diabetic Nephropathies; Glucosamine; Glycogen; Glycogen Storage Disease; Glycoproteins; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Molecular Sequence Data; Sucrase-Isomaltase Complex; Trisaccharides | 1994 |
Cipaglucosidase Alfa: First Approval.
Topics: 1-Deoxynojirimycin; Adult; Enzyme Replacement Therapy; Glycogen; Glycogen Storage Disease Type II; Humans | 2023 |
15 other study(ies) available for 1-deoxynojirimycin and glycogen
| Article | Year |
|---|---|
Hormonal control of cardiac lipolysis by glyco(geno)lysis.
Topics: 1-Deoxynojirimycin; Animals; Glucagon; Glucosamine; Glycerol; Glycogen; Glycolysis; Hypoxia; In Vitro Techniques; Lactates; Lipolysis; Myocardium; Rats | 1990 |
The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme.
Topics: 1-Deoxynojirimycin; 1,4-alpha-Glucan Branching Enzyme; Cytosol; Glucosamine; Glucose; Glucosyltransferases; Glycogen; Glycoside Hydrolase Inhibitors; Liver; Molecular Structure; Phosphorylation | 1989 |
Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Binding, Competitive; Carcinoma, Hepatocellular; Fibroblasts; Glucosamine; Glycogen; Glycoside Hydrolase Inhibitors; Humans; Imino Pyranoses; Immunohistochemistry; Kinetics; Liver Neoplasms; Lysosomes; Microscopy, Electron; Molecular Weight; Tumor Cells, Cultured | 1989 |
Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states.
Topics: 1-Deoxynojirimycin; Adenosine Monophosphate; Amino Acid Sequence; Animals; Binding Sites; Catalysis; Crystallography, X-Ray; Enzyme Inhibitors; Glucosamine; Glycogen; Kinetics; Models, Molecular; Muscle, Skeletal; Phosphates; Phosphorylases; Protein Conformation; Rabbits; Tetrazoles | 1996 |
Inhibition of glycogenolysis by a glucose analogue in the working rat heart.
Topics: 1-Deoxynojirimycin; Animals; Coronary Circulation; Depression, Chemical; Enzyme Inhibitors; Glucosamine; Glucose; Glycogen; Glycogen Debranching Enzyme System; Heart; Insulin; Lactates; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Perfusion; Rats; Rats, Wistar | 1997 |
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts.
Topics: 1-Deoxynojirimycin; Animals; Collateral Circulation; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Hemodynamics; Lactic Acid; Male; Molecular Structure; Myocardial Infarction; Rabbits; Risk Factors | 1998 |
A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits.
Topics: 1-Deoxynojirimycin; Animals; Dose-Response Relationship, Drug; Glucosamine; Glycogen; Hemodynamics; Hypoglycemic Agents; Imino Pyranoses; Lactic Acid; Male; Myocardial Infarction; Myocardium; Rabbits | 1999 |
N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
Topics: 1-Deoxynojirimycin; Animals; Carbon Radioisotopes; Cell Division; Disaccharidases; Enzyme Inhibitors; Female; Glycogen; Glycosphingolipids; Humans; Liver; Lymphocytes; Mice; Mice, Inbred C57BL; Tissue Distribution | 2000 |
Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Biological Transport; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Isoenzymes; Lactates; Male; Myocardial Infarction; Myocardium; Protein Kinase C; Rabbits; Time Factors | 2001 |
Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits.
Topics: 1-Deoxynojirimycin; Animals; Combined Modality Therapy; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart Ventricles; Ischemia; Ischemic Preconditioning, Myocardial; Lactic Acid; Myocardial Infarction; Rabbits | 2001 |
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.
Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blood Flow Velocity; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart; Lactic Acid; Male; Myocardial Ischemia; Myocardial Reperfusion; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Dysfunction, Left | 2000 |
Inhibition of glycogen breakdown by imino sugars in vitro and in vivo.
Topics: 1-Deoxynojirimycin; Animals; Female; Glycogen; Glycoside Hydrolase Inhibitors; Mice; Mice, Inbred C57BL | 2004 |
The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Buffers; Disease Models, Animal; Enzyme Activation; Enzyme Stability; Glycogen; Glycogen Storage Disease Type II; Half-Life; Humans; Mice; Mice, Knockout; Protein Denaturation; Rats; Recombinant Proteins | 2012 |
The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
Topics: 1-Deoxynojirimycin; Administration, Oral; Animals; Biocatalysis; Biological Availability; Chlorocebus aethiops; COS Cells; Disease Models, Animal; Endoplasmic Reticulum; Enzyme Stability; Gene Knockout Techniques; Glucan 1,4-alpha-Glucosidase; Glycogen; Glycogen Storage Disease Type II; Humans; Isoenzymes; Lysosomes; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Protein Transport; Proteolysis | 2014 |
Improved efficacy of a next-generation ERT in murine Pompe disease.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Disease Models, Animal; Enzyme Replacement Therapy; Female; Glycogen; Glycogen Storage Disease Type II; Humans; Lysosomes; Male; Mannosephosphates; Mice; Mice, Knockout; Muscle, Skeletal; Rats; Rats, Sprague-Dawley | 2019 |